Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Trial Profile

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; First in man
  • Acronyms NEPHSTROM
  • Most Recent Events

    • 08 Aug 2017 New trial record
    • 02 Aug 2017 According to an Orbsen Therapeutics media release, OBRCEL-M, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing.
    • 02 Aug 2017 According to an Orbsen Therapeutics media release, this trial is led by the renowned nephrologist, Professor Giuseppe Remuzzi at the Mario Negri Institute in Bergamo, Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top